{'fraction_non_alphanumeric': 0.0297951582867784, 'fraction_numerical': 0.0, 'mean_word_length': 5.560975609756097, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Letter to the editors on ‘Clinical efficacy of lenvatinib for the treatment of radioiodine‐refractory thyroid carcinoma: A systematic review and meta‐analysis of clinical trials’

We read the recent study "Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials" by Zhipeng Yan, et al. for the evaluation of lenvatinib in the treatment of radioiodine-refractory thyroid carcinoma. This article is protected by copyright. All rights reserved.